



**amarin**  
AMARIN TECHNOLOGIES S.A.


Over 30 years enabling more people to have a better life quality

Committed to provide **more people with access to a better quality of life**, through efficient pharmaceutical products that we develop in Latin America and for the world.




# SERVICES

Amarin Technologies S.A. develops topical and transdermal pharmaceutical products, using its proprietary drug delivery technologies and know-how in order to offer both innovative formulations of well-established drugs or generic versions of commercialized products.



Development under  
contract



Co- development



Out licensing of own  
developed products



# TECHNOLOGIES

The Company target is the development and manufacture of patent-protected innovative formulations of well-known drugs and generic versions of transdermal and topical brand products.

Bilayer Drug-in-  
Adhesive TDS



Monolayer Drug-  
in-Adhesive TDS

TDS for delivery of  
liquid drugs




Semisolid  
formulations



# WHY AMARIN?





We are a professional partner for your pharmaceutical product development projects, serious and reliable, confirmed by over 30 years of remarkable experience.



# VALUES



## Professionalism

We are pharma professionals, experts dedicated to the development of efficient pharmaceutical products for more than 30 years. Highly trained to carry out our work in an ethical, serious and dedicated way.




## Transparency

This value runs through everything we do, from our work developing or manufacturing our products, to the relationship with our customers, partners and allies. Transparency and trust have always been vital to the success and development of our business relationships.



## Commitment


We keep our word, we are responsible and committed to our goals, clients and the community. Our history and clients guarantee our reliability.




## Flexibility

As a niche player, flexibility is a key value that characterizes us since we want to offer our clients the adaptability they need for the development of their projects.

# HISTORY & MILESTONES





## R&D activities

are carried out according to international standards -cGMP, cGLP and cGCP-; reinforced by 30 years of experience in the controlled release field.

## Manufacturing Activities

are achieved in a facility of about 1200 m<sup>2</sup>, located in Buenos Aires. These facilities comprise: Manufacturing Plant, Pharmaceutical Development, Analytical Development, QA/QC laboratory.

## Qualified Staff

including Pharmacists, Chemists, Statisticians, MDs and university students, is our distinctive mark to ensure expertise in the transdermal niche market.

## Multi-feature Patents

filed in major and highly-regulated markets around the world (including US and Europe).



# Partner with us

We offer expertise and experience, and at the same time, flexibility and the ability to adapt to customer needs.

*You know what your market and business need. Amarin is the right option to partner with, because as a medium-size player, we offer the flexibility you need to carry out your development projects, while providing professional and specialized expertise in the transdermal niche market.*



# OUR CLIENTS

**teva** **SANDOZ** A Novartis Division

**ferrer** **MERCK**

 **ASOFARMA**

 **HELM**

 **STADA**

 **GEDEON RICHTER**

 **cinfa**



# OUR CLIENTS

“

*I have been collaborating with Amarin Technologies, S.A. for approximately six years and have visited its site in Buenos Aires, Argentina. I have found the leadership and team to be professional, knowledgeable, committed, flexible and extremely reliable. They have proven that they are capable of developing complex, quality transdermal delivery systems and I recommend Amarin Technologies as a business partner.*

”

**VINCENT MANCINELLI II**  
President  
Rhodes Pharmaceuticals, US



# OUR CLIENTS

“

*I have followed developments at Amarin Technologies for nearly 30 years. They grew from a small laboratory developing transdermal systems into a respectable company with a modern manufacturing facility supplying patches for Latin-American and European markets. It has been a pleasure to deal with Amarin's managers and I trust the company will also do well in the future.*

”

**RAINER HOFFMANN**

Formerly President of Knoll  
Pharmaceutical Company, Whippany,  
NJ and LTS Corporation. West  
Caldwell, NJ.



# OUR CLIENTS

“

*I have worked with Amarin since 2006. Throughout that time they have been completely committed to our projects and have added value at every stage of product development. Their professionalism, flexibility, initiative and creativity have been pivotal in helping us achieve our goals.*

”

ANDREW GARDINER  
Chief Executive Officer  
Syntropharma Ltd.



# OUR CLIENTS

“

*Based on our positive experience throughout the years working together, where we could see the commitment and professionalism of Amarin, we consider this company as a strategic partner for any transdermal project.*

”

OMAR CORAZZA  
Global Purchase Manager  
Tecnofarma



# OUR CLIENTS

**“** *I have partnered with Amarin for the development of multiple complex transdermal products. They proved over and over again the strong technical skills needed to fully develop and commercialize challenging formulations. In addition, they've shown a serious commitment to the success of their partnerships. I would welcome the opportunity to work with Amarin again.* **”**


**JOHN PECK**

Vice-President, Business Development, Nevakar Inc.  
Former Head of BD and Product Selection for Hikma, US



# AVAILABLE PRODUCTS

Our offering consists of products available at different development stages, which can be further developed in our partnership throughout the following mentioned services:



Development under  
contract



Co- development



Out licensing of own  
developed products



# MARKETED PRODUCTS

| PRODUCT                           | TERRITORY | REFERENCE PRODUCTS       | THERAPEUTIC USE                                                          |
|-----------------------------------|-----------|--------------------------|--------------------------------------------------------------------------|
| FENTANYL TDS                      | Europe    | Durogesic® (Janssen)     | Management of pain in opioid-tolerant patients                           |
| RIVASTIGMINE TDS *                | Latam     | Exelon® (Novartis)       | Alzheimer disease. Dementia associated with Parkinson's disease          |
| BUPRENORPHINE TDS * - 7 day patch | Latam     | Butrans® (Purdue Pharma) | Moderate to severe chronic pain                                          |
| DICLOFENAC SODIUM GEL 1%          | USA       | Voltaren® (GSK)          | Osteoarthritis, soft-tissue rheumatism, traumas                          |
| DICLOFENAC SODIUM GEL 5%          | Argentina | Diclac® (Hexal)          | Osteoarthritis, soft-tissue rheumatism, traumas                          |
| ESTRADIOL GEL 0.06%               | Argentina | Estrogel® (Ascend)       | Hormonal replacement therapy                                             |
| TESTOSTERONE GEL                  | Argentina | Androgel® (Abbvie)       | Replacement therapy for deficiency or absence of endogenous testosterone |

\* Lower drug content and smaller patch size than the reference product.



# DEVELOPED FORMULATIONS

| PRODUCT               | REFERENCE PRODUCTS         | THERAPEUTIC USE                                                          |
|-----------------------|----------------------------|--------------------------------------------------------------------------|
| ROTIGOTINE TDS        | Neupro® (UCB)              | Parkinson disease                                                        |
| METHYLPHENIDATE TDS * | Daytrana® (Noven)          | Attention Deficit Hyperactivity Disorder (ADHD)                          |
| SELEGILINE TDS *      | Emsam® (Dey L.P./Somerset) | Major depressive disorders                                               |
| TESTOSTERONE GEL      | Androgel® (Abbvie)         | Replacement therapy for deficiency or absence of endogenous testosterone |

\* Lower drug content and smaller patch size than the reference product.



# PHARMACEUTICAL DEVELOPMENT STAGE PRODUCTS

| PRODUCT                                                | REFERENCE PRODUCTS                         | THERAPEUTIC USE                                                         |
|--------------------------------------------------------|--------------------------------------------|-------------------------------------------------------------------------|
| RIVASTIGMINE MULTIDAY TDS<br>(twice a week and weekly) | Rivalif® (Luye)                            | Alzheimer disease. Dementia associated with Parkinson disease           |
| DONEPEZIL MULTIDAY TDS                                 | Adlarity® (Corium) / Donerion® (Icure)     | Alzheimer disease. Dementia associated with Parkinson disease           |
| IBUPROFEN TDS                                          | Nurofen® (Reckitt Benckiser)               | Short-term symptomatic treatment of local pain in acute muscular strain |
| OPIOID ABUSE<br>DETERRENT TDS                          | Innovator                                  | Management of pain in opioid-tolerant patients                          |
| LIDOCAINE TDS 5%                                       | Lidoderm® (Endo)<br>Versatis® (Grunenthal) | Pain relief associated with post-herpetic neuralgia                     |
| DICLOFENAC SODIUM TDS                                  | Zichthoru® (Hisamitsu)                     | Analgesia in various cancers                                            |





# CONTACT US

Germán Müller

Business Development Manager

✉ german.muller@amarintech.com.ar

☎ + 54 911 4588 6500 - ext. 136

🌐 [www.amarintech.com](http://www.amarintech.com)